Skip to main content
Fig. 4 | BMC Complementary Medicine and Therapies

Fig. 4

From: Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response

Fig. 4

H3K27me3 related cantharidin treatment target prediction analysis in HCC. (A) Venn diagram shows the genes of liver carcinoma and H3K27me3 related cantharidin treatment targets. (B) The expression of these targets in LIHC. Red represents high expression; blue represents low expression. P < 0.05 is considered significant. (C) Proteins expression of significantly up-regulated genes in LIHC. (D) These genes expression in cantharidin treated HepG2 cell. The * P < 0.05 was regarded as statistically significant. (E) H3K27me3 is dramatically enriched in these genes promoters based on the ChIP-seq results in HepG2

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us